Praxbind

Praxbind

idarucizumab

Manufacturer:

Boehringer Ingelheim

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Idarucizumab
Indications/Uses
Adults treated w/ Pradaxa (dabigatran etexilate) where rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures & in life-threatening or uncontrolled bleeding.
Dosage/Direction for Use
5 g (2 x 2.5 g/50 mL) via IV as 2 consecutive infusions over 5-10 min each or as a bolus inj. Flush IV line w/ NaCl 9 mg/mL (0.9%) soln prior to & at the end of infusion. Recurrent bleeding w/ prolonged clotting times/if potential re-bleeding would be life-threatening & prolonged clotting times are observed/2nd emergency surgery or urgent procedure w/ prolonged clotting times Consider 2nd 5 g dose. Restarting antithrombotic therapy: Pradaxa can be re-initiated after 24 hr & other antithrombotic therapy (eg, low-molecular wt heparin) can be started at any time if patient is clinically stable & adequate haemostasis has been achieved.
Special Precautions
Hypersensitivity. Hereditary fructose intolerance. Consider resumption of anticoagulant therapy in patients treated w/ dabigatran that may have underlying disease state that may predispose to thromboembolic events. May cause transient proteinuria. Patients on a controlled Na diet. Lactation.
MIMS Class
Antidotes & Detoxifying Agents / Haemostatics
ATC Classification
V03AB37 - idarucizumab ; Belongs to the class of antidotes. Used to reverse anticoagulant effects of dabigatran.
Presentation/Packing
Form
Praxbind soln for inj 2.5 g/50 mL
Packing/Price
2 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in